Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 7/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.52 |
| ▸ | HTR3B | O95264 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | PNMT | P11086 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483536 | 0.87 | MIF (0.74) | MIFCYP3A4TRPA1ALDH1A1HPGD | |
| SCHEMBL6657463 | 0.85 | HTR3E (0.49) | MIFCYP3A4TRPA1ALDH1A1HPGD | |
| SCHEMBL4701003 | 0.81 | MIF (0.67) | MIFTRPA1HTR3EHTR3BHTR3A | |
| SCHEMBL3924560 | 0.80 | HTR3E (0.52) | MIFCYP3A4HTR3EHTR3BHTR3A | |
| SCHEMBL30483624 | 0.80 | HTR3E (0.52) | MIFCYP3A4HTR3EHTR3BHTR3A | |
| SCHEMBL28709411 | 0.79 | MIF (0.52) | MIFCYP3A4TRPA1ALDH1A1HPGD | |
| SCHEMBL25333223 | 0.78 | MIF (0.69) | MIFCYP3A4TRPA1ALDH1A1HPGD | |
| SCHEMBL10651510 | 0.78 | MIF (0.62) | MIFCYP3A4TRPA1ALDH1A1HPGD | |
| SCHEMBL2341886 | 0.78 | MIF (0.62) | MIFCYP3A4TRPA1ALDH1A1HPGD | |
| SCHEMBL1551628 | 0.78 | MIF (1.00) | MIFCYP3A4TRPA1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010065329-A2 | NANOPARTICLES FOR CANCER TREATMENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | WO | claimed |
| US-20060241178-A1 | Compositions and methods for treating lung cancer | IMMUNEGUARD LLC (US) | 2006-10-26 | — | — | US | claimed |
| WO-2004060365-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER | AMERICAN HEALTH FOUNDATION (US) | 2004-07-22 | — | — | WO | claimed |
| WO-2023210570-A1 | PLANT STOMATAL OPENING REGULATOR | 国立大学法人東海国立大学機構 | 2023-11-02 | — | — | WO | disclosed |
| WO-2020021544-A1 | CANNABIDIOL AND METHYLTHIO-BUTYL-ISOTHIOCYANATE FOR TREATING INFLAMMATORY DISEASES | BOL PHARMA LTD. (IL) | 2020-01-30 | — | — | WO | disclosed |
| US-20130158111-A1 | Compositions and Methods for Depleting Mutant p53 | GEORGETOWN UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| US-20120208879-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING PSORIASIS | GAVISH-GALILEE BIO APPLICATIONS LTD. (IL) | 2012-08-16 | — | — | US | disclosed |
| US-8158161-B2 | Methods and pharmaceutical compositions useful for treating psoriasis | S.U.L.V.E. LTD. (IL) | 2012-04-17 | — | — | US | disclosed |
| EP-1465882-B1 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010065329-A2 | NANOPARTICLES FOR CANCER TREATMENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2009-10-29 | — | — | US | disclosed |
| WO-2001051527-A1 | PROCATALYSTS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001051526-A1 | PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001051529-A1 | PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6194438-B1 | ANTITUMOR AGENTS; ANTICANCER AGENTS; FARNESYL-PROTEIN TRANSFERASE INHIBITOR | PFIZER INC. | 2001-02-27 | — | — | US | disclosed |
| WO-2000075203-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075202-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075204-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| EP-1006113-A1 | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth | Pfizer Products Inc. (US) | 2000-06-07 | — | — | EP | disclosed |
| EP-0359505-A1 | Dopamine-beta hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1990-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | MC4R, MC3R, MC1R | MIF 277/4885CYP3A4 203/4885TRPA1 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.